Navigation Links
Pharmasset to Present at Four Upcoming Investor Conferences
Date:9/8/2009

masset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog currently completing Phase 1 clinical studies and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adver
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to a new market ... global orthobiologics market was valued at USD 3,754.6 million in ... 5,519.9million in 2019at a CAGR of 5.9% from 2013 to ... and above is afflicted by bone and joint disorders, and ... 2020. This has and will continue to increase the demand ...
(Date:8/29/2014)... Three Lawrence Livermore researchers have received ... R&D Award for their research in producing ... , Shared with collaborators from the National Renewable ... Las Vegas (UNLV), the award recognizes the team ... production and corrosion processes. , These models have ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 SPIE Fellow ... Physics and Optical Science and Director of the Center ... North Carolina at Charlotte, and co-founder and Chairman of ... serve as the 2015 Vice President of SPIE, the ... President Philip Stahl announced recent election results at the ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... two-year state budget signed into law Monday by Gov. ... Wisconsin technology firms by changing how corporate income from ... Technology Council. , ,With bipartisan support from the ... factor" sales apportionment for corporate income to technology and ...
... Wis. Sir Winston Churchill was once ... all the others that have been tried." Certainly one ... a confusion of popularity with leadership, and this poses ... the snippy comments, eroding voter participation and the occasional ...
... Fiserv, Inc ., a provider information management ... industries has signed a definitive agreement to acquire ... payment services. , ,BillMatrix, founded in 1994, provides ... customers to get immediate credit for bills paid online ...
Cached Biology Technology:`Single-sales factor' extends tax treatment to tech, service firms 2`Single-sales factor' extends tax treatment to tech, service firms 3IT - Does everybody get a vote? 2IT - Does everybody get a vote? 3
(Date:9/1/2014)... microscopy revealed the presence of tiny blob-like structures that ... still don,t know what they do even though ... be crucial to the life of a cell, and ... In the Journal of Cell Biology , two ... backgrounds, from biophysics to cell biology, to focus their ...
(Date:8/31/2014)... highly infectious bacteria C. diff , that causes ... a team at the University of Leicester. , Using ... it is possible to identify the unique ,smell, of ... diagnosis of the condition., What is more, the Leicester ... strains of the disease simply from their smell ...
(Date:8/31/2014)... several decades, malaria diagnosis has changed very little. After taking ... blood across a glass slide, stains it with a special ... which causes the disease. This approach gives an accurate count ... important measure of disease severity but is not ideal ... team from the Singapore-MIT Alliance for Research and Technology (SMART) ...
Breaking Biology News(10 mins):Scientists call for investigation of mysterious cloud-like collections in cells 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3
... - When a reactor in the Chernobyl nuclear power ... Soviet republic of Ukraine, radioactive elements were released in ... and even eastern portions of North America. , ... Reserve University traveled to Sweden and Poland to gain ...
... [October 1, 2008] Sirtris, a GSK company focused ... diseases of aging such as Type 2 Diabetes, announced ... the growing body of sirtuin research and its potential ... Diabetes, mitochondrial disorders, inflammation, cancer, and heart disease. ...
... employs shade trees may improve crops, resistance to temperature ... trigger, according to an article published in the October ... B. Lin, Ivette Perfecto, and John Vandermeer, of the ... conclusions could be applicable to other economically important crops, ...
Cached Biology News:Case Western Reserve University researchers track Chernobyl fallout 2Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery 2